NOREL

In Vitro and in Vivo Screens for Novel Regulators in Leukemia (NOREL)

Coordinatore	KOBENHAVNS UNIVERSITET    more  Organization address postcode: 1017 contact info Titolo: Mr. Nome: Ivan Cognome: Kristoffersen Email: send email Telefono: +45 35322626 Fax: +45 35324612
Nazionalità Coordinatore	Denmark [DK]
Totale costo	219˙590 €
EC contributo	219˙590 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2010-IEF
Funding Scheme	MC-IEF
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-04-01   -   2014-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	KOBENHAVNS UNIVERSITET	DK	coordinator	219˙590.40

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Leukemic cells, similar to other types of cancer cells, are characterized by aberrant epigenetic changes, which often lead to abnormal expression of oncogenes and tumor suppressor genes. The goal of this project is to identify and characterize new regulators of normal and malignant hematopoiesis. We propose two complementary loss-of-function screens, using shRNA vectors against two groups of histone modifying enzymes, histone methyltransferases and histone demethylases.

We plan to perform an in vitro shRNA screen, infecting mouse primary cells with lentiviruses based on single pLKO.1 vectors. We will assess the effect of down-regulation of a specific protein by flow cytometry analysis. In parallel, we will carry out an in vivo shRNA screen in a mouse model of human acute myeloid leukemia (AML). Mouse leukemic cells will be infected with a pooled retroviral shRNA library and transplanted into a small number of recipient mice. When the recipient mice develop AML, the leukemic cells will be harvested and high-throughput sequencing of shRNAs will be used to determine shRNAs depleted or enriched during initiation and progression of AML.

Selected candidate genes will be validated and further characterized using in vitro and in vivo assays. Moreover, we will search for molecular mechanisms mediating the function of validated candidates in normal hematopoiesis and/or leukemia. I strongly believe that this project can lead to a discovery of novel oncogenes and/or tumor suppressors involved in AML, and potentially also to design of novel therapies for leukemia treatment.'

Introduzione (Teaser)

The incidence of acute myeloid leukaemia (AML), the most common acute leukaemia affecting adults, increases with age. Discovery of novel oncogenes and/or tumour suppressors involved in AML can lead to design of novel therapies for leukaemia treatment.